Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Pré-Publication, Document De Travail Année : 2021

Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells

Résumé

Background: Interferon (IFN) pathway activation in tumors can have dual, sometimes opposing, influences on immune responses. Therapeutic inhibition of programmed cell death ligand (PD-L1)-a treatment that reverses PD-1-mediated suppression of tumor-killing T-cells-is linked to alterations in IFN signaling; however, less is known about the role of IFNs after treatment resistance. Since IFN-regulated intracellular signaling can control extracellular secretory programs in tumors to modulate immunity, we examined the consequences of PD-L1 blockade on IFNrelated secretory changes in preclinical models of acquired resistance.

Domaines

Cancer
Fichier principal
Vignette du fichier
2021.07.01.450417v2.full.pdf (4.48 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04387866 , version 1 (11-01-2024)

Licence

Identifiants

Citer

Yuhao Shi, Melissa Dolan, Michalis Mastri, Amber Mckenery, James W Hill, et al.. Acquired resistance to PD-L1 inhibition is associated with an enhanced type I IFN-stimulated secretory program in tumor cells. 2023. ⟨hal-04387866⟩
37 Consultations
7 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More